Marker Therapeutics, Inc.

Monthly Archives: February 2015

TapImmune Appoints John Bonfiglio as Strategic Advisor

…Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise

SEATTLE, Feb. 25, 2015 – TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John Bonfiglio, Ph.D., MBA as a Strategic Advisor. John is a highly successful Biotech CEO with broad experience in corporate strategy and financing, market interactions and business development.

Read More

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

…SEATTLE, Feb. 23, 2015 – TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to announce Patrick D. Yeramian, MD, MBA, has been appointed Consulting Medical Director. He will lead TapImmune’s clinical development programs for folate receptor alpha and Her2/neu multi-epitope cancer technologies.

Read More

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

…TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

Seattle, WA – February 20, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today Dr. Glynn Wilson, Chairman & CEO of TapImmune, will present an update on the progress of clinical programs on Monday, February 23, 2015 at 12:30 P.M .

Read More

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

…TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

Seattle, WA & NY, NY – February 19, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today the Company’s management team has selected New York City based PCG Advisory (PCG) as agency of record for Investor, Public, and Social Media Relations.

Read More